Kallikrein-6 (EC 3.4.21.-) (Neurosin) (Protease M) (SP59) (Serine protease 18) (Serine protease 9) (Zyme)
1_MKKLM 6_ VVLSL 11_ IAAAW 16_ AEEQN 21_ KLVHG 26_ GPCDK 31_ TSHPY 36_ QAALY 41_ TSGHL 46_ LCGGV 51_ LIHPL 56_ WVLTA 61_ AHCKK 66_ PNLQV 71_ FLGKH 76_ NLRQR 81_ ESSQE 86_ QSSVV 91_ RAVIH 96_ PDYDA 101_ ASHDQ 106_ DIMLL 111_ RLARP 116_ AKLSE 121_ LIQPL 126_ PLERD 131_ CSANT 136_ TSCHI 141_ LGWGK 146_ TADGD 151_ FPDTI 156_ QCAYI 161_ HLVSR 166_ EECEH 171_ AYPGQ 176_ ITQNM 181_ LCAGD 186_ EKYGK 191_ DSCQG 196_ DSGGP 201_ LVCGD 206_ HLRGL 211_ VSWGN 216_ IPCGS 221_ KEKPG 226_ VYTNV 231_ CRYTN 236_WIQKT
1: Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis